NanoViricides Inc. (NNVC)

[Its_lose_not_loose]

https://www.equities.com/videos/nanoviricides-inc

Seymour's flippancy in this interview is astounding. He speaks of the diseases with such joviality, it's amazing anybody could take him seriously about anything else.

Also, very condescending to the interviewer.

At 2:33 he says "We have a drug for that." [referring to Dengue hemorrhagic fever]. Really? Where is it?

5:33 "We trade anywhere from 250,000 to 2,000,000 shares a day." BWAHAHAHAHAHAHAHAHA

7:15 "From there [Phase IIa trials] the pharma companies come swarming, as they've already swarmed us." Have they? Is this just hyperbole and wishful thinking? Over-optimism? Sounds to me like a statement that just isn't true. Prove me wrong.

8:17 "[I] Started taking care of AIDS patients in 1980." He must've been an early responder. According to Wikipedia: "April 24, [1980] San Francisco resident Ken Horne, the first AIDS case in the United States to be recognized at the time, is reported to the Center for Disease Control with Kaposi's sarcoma (KS). He was also suffering from Cryptococcus." It's fascinating to learn that Seymour was on the front line of caring for AIDS patients in the same year it was first recognized in the US.

His constant use of present tense, as if these drugs already exist and are in use, is so misleading, it's astounding.

Fortunately, he has poetic license, carte blanche or whatever you want to call it, to say whatever he wants to without repercussion. His license to lie is in every one of NNVC's press releases.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.